ALKN 204
Alternative Names: ALKN-204Latest Information Update: 28 Mar 2025
At a glance
- Originator Shanghai Allink Biotherapeutics
- Class Antibodies; Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 28 Mar 2025 Preclinical trials in Solid tumours in China (unspecified route) (Shanghai Allink Biotherapeutics pipeline, March 2025)